Noha H. Sayed

Noha H. Sayed

Auto-generated profile, based on publicly available information

Noha H. Sayed

Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

5 April 2021 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
NFNevine Fathy
Nevine Fathy
MKMona A. Kortam
Mona A. Kortam
OSOlfat G. Shaker
Olfat G. Shaker
NSNoha H. Sayed
Noha H. Sayed

19 January 2022 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
OAOmaima A. Ahmedy
Omaima A. Ahmedy
HSHeba H. Salem
Heba H. Salem
NSNoha H. Sayed
Noha H. Sayed
SISherehan Ibrahim
Sherehan Ibrahim

13 September 2022 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
HHHebatullah Helmy
Hebatullah Helmy
NSNermin Abdel Hamid Sadik
Nermin Abdel Hamid Sadik
LBLaila Badawy
Laila Badawy
NSNoha H. Sayed
Noha H. Sayed

11 January 2025 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
NSNoha H. Sayed
Noha H. Sayed
OSOlfat Shaker
Olfat Shaker
MAMai A. ABD-ELMAWLA
Mai A. ABD-ELMAWLA
AGAhmed Gamal
Ahmed Gamal
NFNevine Fathy
Nevine Fathy
The current study was deployed to evaluate the role of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and miR-155, along with the inflammatory markers, TNFα and IL-6, and the adhesion molecule, cluster of differentiation 106 (CD106), in Behçet’s disease (BD) pathogenesis. The study also assessed MALAT1/miR-155 as promising diagnostic and prognostic biomarkers for BD. The current retrospective case–control study included 74 Egyptian BD patients and 50 age and sex-matched controls. Blood samples were collected, and then, serum samples were separated for further biochemical and molecular investigations. The gene expression of MALAT1 and miR-155 was measured using qRT-PCR, whereas the levels of TNFα, IL-6, and CD106 were estimated using ELISA technique. MALAT1 was significantly downregulated, whereas miR-155 was upregulated among BD patients, compared with control subjects. Levels of TNFα, IL-6, and CD106 were elevated in BD patients. Further downregulation in MALAT1 together with upregulation of miR-155 was observed in active BD patients, relative to the inactive group. Receiver-operating-characteristic analysis revealed that MALAT1 and miR-155 could discriminate BD patients from controls, on the one hand, and active from inactive BD patients, on the other hand. MALAT1 was negatively correlated with TNFα, IL-6, and CD106, while miR-155 was positively correlated with them. Logistic regression analyses demonstrated miR-155 as a significant independent predictor of BD susceptibility, and MALAT1 as an independent negative predictor of BD activity. For the first time, the current research enlightens the role of MALAT1 and miR-155 in BD pathogenesis via impacting IL-6/TNF-α/CD-106 signaling. As well, MALAT1 and miR-155 could be regarded as novel non-invasive biomarkers that may improve BD diagnosis and prognosis. Key Points•MALAT1/miR-155 exerts potential role in Behçet’s disease. •MALAT1/miR-155 are promising biomarkers for Behçet’s disease. •MALAT1/miR-155 targets IL-6/TNF-α/CD-106 signaling.

1 July 2025 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
MSMuhammad A.E. Saad
Muhammad A.E. Saad
RSRabab Sayed
Rabab Sayed
AEAyman E. El-Sahar
Ayman E. El-Sahar
NSNoha H. Sayed
Noha H. Sayed
MKMona A. Kortam
Mona A. Kortam
NFNevine Fathy
Nevine Fathy